Drug Information Analysis Service

Primary degenerative dementia of the Alzheimer type. In: Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987: 119–21.

Rathmann KL Conner CS . Alzheimer's disease: Clinical features, pathogenesis, and treatment. Drug Intell Clin Pharm 1984; 18: 684–91.

Messing RB Jensen RA Martinez JL Spiehler VR Vasquez BJ Soumireu-Mourat B Naloxone enhancement of memory. Behav Neurol Biol 1979; 27: 266–75.

Reisberg B Ferris SH Anand R Pervez M DeLeon MJ Roberts E . Naloxone effects on primary degenerative dementia (PDD). Psychopharmacol Bull 1983; 19: 45–7.

Reisberg B Ferris SH Anand R Pervez M Geibel V DeLeon MJ . Effects of naloxone in senile dementia: A double-blind trial. N Engl J Med 1983; 308: 721–2.

Blass J Reding M Drachman D . Effects of naloxone in senile dementia: A double-blind trial (letter). N Engl J Med 1983; 309: 556.

Panella JJ Blass JP . Lack of clinical benefit from naloxone in a dementia day hospital (letter). Ann Neurol 1984; 15: 308.

Sandyk R Allender J Bamford CR . Effects of the opiate antagonist naloxone on learning and memory in patients with multi-infarct dementia (letter). Postgrad Med J 1987; 63: 716–7.

Steiger WA Mendelson M Jenkins T Smith M Gay R . Effects of naloxone in treatment of senile dementia (letter). J Am Geriatr Soc 1985; 33: 155.

Tariot PN Sunderland T Weingartner H Murphy DL Cohen MR Cohen RM . Naloxone and Alzheimer's disease. Arch Gen Psychiatry 1986; 43: 727–32.

Cutler NR . Methodological concerns: Evaluating central nervous system (CNS) active compounds in Alzheimer's disease (AD). Prog Clin Biol Res 1989; 317: 1311–7.

Swash M Brooks DN Day NE Frith CD Levy R Warlow CP . Clinical trials in Alzheimer's disease. A report from the Medical Research Council Alzheimer's Disease Clinical Trials Committee., J Neurol Neurosurg Psychiatry 1991; 54: 178–81.

Riggs BL Melton LJ . Clinical heterogeneity of involutional osteoporosis: Implications for preventive therapy. J Clin Endocrinol Metabol 1990; 70: 1229–32.

Mandel FP Davidson BJ Erik Y Judd HL Meldrum DR . Effects of progestins on bone metabolism in postmenopausal women. J Reprod Med 1982; 27: 511–4.

Lobo RA McCormick W Singer F Roy S . Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. J Am Coll Obstet Gynecol 1984; 63: 1–5.

McNeeley SG Schinfeld TG Stovall FW Ling FW Buxton BH . Prevention of osteoporosis by medroxyprogesterone acetate in postmenopausal women. Int J Gynecol Obstet 1991; 34: 253–6.

Gallagher JC Kable WT Goldgar D . Effect of progestin therapy on cortical and trabecular bone: Comparison with estrogen. Am J Med 1991; 90: 171–8.

Ernster VL Bush TL Huggins GR Hulka BS Kelsey JL Schotten-Feld D . Benefits and risks of menopausal estrogen and/or progestin hormone use. Prevent Med 1988; 17: 201–23.